Abstract Details

Title Increased Risk of Suicidal Ideation in Patients with Spinocerebellar Ataxias

Topic Movement Disorders

Presentation(s) S2 - Movement Disorders: Epidemiology and Clinical Aspects (2:36 PM-2:48 PM)

Poster/Presentation
Number 009

Background Suicidal ideation has been identified in a variety of neurological disorders and has tremendous impacts on patients and their families. However, suicidality has not been extensively studied in patients with SCAs.

Objective To test if individuals with spinocerebellar ataxias (SCAs) are at an increased risk for suicidal ideation.

Design/Methods We studied 781 patients with genetically confirmed SCAs from the Clinical Research Consortium for the Study of Cerebellar Ataxia cohort. We investigated the prevalence of suicidal ideation in SCA1, 2, 3, and 6, and compared that to the general population using Fisher’s Exact test to generate an odds ratio. We investigated the clinical characteristics that may contribute to suicidal ideation in SCAs, including age, disease duration, sex, ataxia severity, and PHQ-8 scores (measured over a two-week period) using Independent sample t-test and the Mann-Whitney U test to compare patients with and without suicidal ideation.

Results Suicidal ideation was present in 11.8% of participants with SCAs, and when compared to the 9.2% in historical controls from the general global population, had an odds ratio of 1.32 (p = 0.002). Suicidal ideation was most prominent in SCA3 cases (odds ratio = 1.74, p = 0.003). SCA patients with suicidal ideation have longer years of disease duration (11.48 ± 6.88 vs. 9.93 ± 8.63, p=0.015), more severe ataxia as rated by the scale for the assessment and rating of ataxia (17.40 ± 8.76 vs. 12.94 ± 7.83, p < 0.001), and more severe depression (10.38 ± 5.72 vs. 4.95 ± 4.80, p < 0.001) than those without suicidal ideation.

Conclusions Suicidal ideation is more prevalent in SCAs than the general population. Our study highlights the importance of screening suicidal risk as part of the clinical evaluation for SCAs.

Authors/Disclosures
Levi Peppel PRESENTER	Mr. Peppel has nothing to disclose.
Ruo-Yah Lai	Ms. Lai has nothing to disclose.
Puneet Opal, MD, PhD (Northwestern University Med Sch)	Dr. Opal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for reata. Dr. Opal has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ACTN. Dr. Opal has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JCI. The institution of Dr. Opal has received research support from NIH. Dr. Opal has received intellectual property interests from a discovery or technology relating to health care.
Jeremy D. Schmahmann, MD, FAAN (Massachusettes General Hospital)	Dr. Schmahmann has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. The institution of Dr. Schmahmann has received research support from National Ataxia Foundation. The institution of Dr. Schmahmann has received research support from Biohaven. Dr. Schmahmann has received intellectual property interests from a discovery or technology relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care. Dr. Schmahmann has received publishing royalties from a publication relating to health care.
Christopher Gomez, MD, PhD (University of Chicago)	Dr. Gomez has nothing to disclose.
Henry L. Paulson, MD, PhD, FAAN (University of Michigan)	Dr. Paulson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Exicure. The institution of Dr. Paulson has received research support from National Institutes of Health. Dr. Paulson has a non-compensated relationship as a Member, Nominating committee with American Neurological Association that is relevant to AAN interests or activities.
Theresa A. Zesiewicz, MD (University of South Florida)	Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
Susan L. Perlman, MD (UCLA)	Dr. Perlman has nothing to disclose.
George R. Wilmot, MD, PhD (Emory University Dept of Neurology)	Dr. Wilmot has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar Therapeutics. The institution of Dr. Wilmot has received research support from Friedrich Ataxia Research Alliance. The institution of Dr. Wilmot has received research support from National Ataxia Foundation. The institution of Dr. Wilmot has received research support from NIH. The institution of Dr. Wilmot has received research support from Reata. The institution of Dr. Wilmot has received research support from Biohaven Pharmaceuticals.
Sarah H. Ying, MD (MEEI)	Dr. Ying has nothing to disclose.
Chiadi U. Onyike, MD (Johns Hopkins University SOM)	Dr. Onyike has received personal compensation for serving as an employee of Rainwater Foundation. Dr. Onyike has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia Pharmaceuticals . Dr. Onyike has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Reata Pharmaceuticals. Dr. Onyike has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Goodell, DeVries, Leech & Dann. The institution of Dr. Onyike has received research support from Alector.
K O. Bushara, MBBS, FRCP (University of Minnesota)	The institution of Prof. Bushara has received research support from Bob Allison Ataxia Foundation.
Michael D. Geschwind, MD, PhD, FAAN (UCSF)	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Karla P. Figueroa (University of Utah)	Ms. Figueroa has nothing to disclose.
Stefan M. Pulst, MD, FAAN (University of Utah)	Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care.
S H. Subramony, MBBS, FAAN (University of Florida)	Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dyne. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Subramony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fallonmedica. The institution of Dr. Subramony has received research support from Reata. The institution of Dr. Subramony has received research support from Retrotope. The institution of Dr. Subramony has received research support from Acceleron. The institution of Dr. Subramony has received research support from Biohaven. The institution of Dr. Subramony has received research support from Pharnext. The institution of Dr. Subramony has received research support from Fulcrum. The institution of Dr. Subramony has received research support from National Ataxia Foundation. The institution of Dr. Subramony has received research support from Friedreich Ataxia Research Alliance. The institution of Dr. Subramony has received research support from Muscular Dystrophy Association. The institution of Dr. Subramony has received research support from Univ of Rochester, MDA. The institution of Dr. Subramony has received research support from Virginia Commonwealth Univ (FDA, Wyck Foundation)). The institution of Dr. Subramony has received research support from Children's Hospital, Philadelphia (FDA). The institution of Dr. Subramony has received research support from Houston Methodist (NIH). The institution of Dr. Subramony has received research support from NIHR01 AR076060-01A1 . The institution of Dr. Subramony has received research support from NIH2R42HD089804-04 . The institution of Dr. Subramony has received research support from NIH R01 AR056973 . The institution of Dr. Subramony has received research support from FSHD Society. The institution of Dr. Subramony has received research support from AAVANTI BIO. The institution of Dr. Subramony has received research support from COHAV FL State Dept of Health.
Antoine Duquette, MD (CHUM)	Dr. Duquette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Reata. The institution of Dr. Duquette has received research support from Actelion. The institution of Dr. Duquette has received research support from Ataxia Canada/FARA.
Tetsuo Ashizawa, MD, FAAN (Methodist Hospital Research Institute)	An immediate family member of Dr. Ashizawa has received personal compensation for serving as an employee of Biopath Holdings. The institution of Dr. Ashizawa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UniQure. The institution of Dr. Ashizawa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cadence. Dr. Ashizawa has received personal compensation in the range of $0-$499 for serving as a Consultant for Astellas. The institution of Dr. Ashizawa has received research support from NIH. The institution of Dr. Ashizawa has received research support from National Ataxia Foundation. The institution of Dr. Ashizawa has received research support from Myotonic Dystrophy Foundation. The institution of Dr. Ashizawa has received research support from Biogen.
Ali G. Hamedani, MD, MHS (Hospital of the University of Pennsylvania)	The institution of Dr. Hamedani has received research support from Michael J. Fox Foundation. The institution of Dr. Hamedani has received research support from NIH. The institution of Dr. Hamedani has received research support from Biogen. The institution of Dr. Hamedani has received research support from Biohaven. The institution of Dr. Hamedani has received research support from NIH.
Marie Y. Davis, MD, PhD (VA Puget Sound)	Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Davis has received research support from NIH NINDS. The institution of Dr. Davis has received research support from University of Washington Institute for Stem Cell and Regenerative Medicine. The institution of Dr. Davis has received research support from VA BLRD. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a study section grant reviewer with NIH. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with Parkinson's Foundation.
Sharan Srinivasan, MD (University of Michigan)	Dr. Srinivasan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Praxis Precision Medicines. Dr. Srinivasan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota Biosciences. Dr. Srinivasan has received research support from American Academy of Neurology.
Matthew R. Burns, MD, PhD (University of Florida)	Dr. Burns has nothing to disclose.
Lauren Moore, PhD (National Ataxia Foundation)	Dr. Moore has nothing to disclose.
Vikram Shakkottai, MD, PhD (University of Texas Southwestern Medical Center)	The institution of Dr. Shakkottai has received research support from National Institutes of Health. Dr. Shakkottai has received publishing royalties from a publication relating to health care.
Liana Rosenthal, MD (Johns Hopkins School of Medicine)	Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata Pharmaceuticals. Dr. Rosenthal has received research support from NIH. Dr. Rosenthal has received research support from Gordon and Marilyn Macklin Foundation. Dr. Rosenthal has received research support from The Daniel B. and Florence E. Green Foundation. Dr. Rosenthal has received research support from National Ataxia Foundation. Dr. Rosenthal has received research support from Michael J. Fox Foundation. Dr. Rosenthal has received research support from Pfizer. Dr. Rosenthal has received research support from Biohaven Pharmaceuticals. Dr. Rosenthal has a non-compensated relationship as a Medical Director, ex-officio Member of the Board with National Ataxia Foundation that is relevant to AAN interests or activities.
Sheng-Han Kuo, MD (Columbia University)	Dr. Kuo has nothing to disclose.
Chi-Ying (Roy) Lin, MD, FAAN (Baylor College of Medicine)	Dr. Lin has a non-compensated relationship as a Secretary with Broadway for Ataxia Foundation (a 501 (c) (3) non-profit organization) that is relevant to AAN interests or activities.